Institute for Experimental and Translational Cardiovascular Imaging, DZHK Centre for Cardiovascular Imaging, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Nat Med. 2022 Oct;28(10):2117-2123. doi: 10.1038/s41591-022-02000-0. Epub 2022 Sep 5.
Cardiac symptoms are increasingly recognized as late complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in previously well individuals with mild initial illness, but the underlying pathophysiology leading to long-term cardiac symptoms remains unclear. In this study, we conducted serial cardiac assessments in a selected population of individuals with Coronavirus Disease 2019 (COVID-19) with no previous cardiac disease or notable comorbidities by measuring blood biomarkers of heart injury or dysfunction and by performing magnetic resonance imaging. Baseline measurements from 346 individuals with COVID-19 (52% females) were obtained at a median of 109 days (interquartile range (IQR), 77-177 days) after infection, when 73% of participants reported cardiac symptoms, such as exertional dyspnea (62%), palpitations (28%), atypical chest pain (27%) and syncope (3%). Symptomatic individuals had higher heart rates and higher imaging values or contrast agent accumulation, denoting inflammatory cardiac involvement, compared to asymptomatic individuals. Structural heart disease or high levels of biomarkers of cardiac injury or dysfunction were rare in symptomatic individuals. At follow-up (329 days (IQR, 274-383 days) after infection), 57% of participants had persistent cardiac symptoms. Diffuse myocardial edema was more pronounced in participants who remained symptomatic at follow-up as compared to those who improved. Female gender and diffuse myocardial involvement on baseline imaging independently predicted the presence of cardiac symptoms at follow-up. Ongoing inflammatory cardiac involvement may, at least in part, explain the lingering cardiac symptoms in previously well individuals with mild initial COVID-19 illness.
心脏症状越来越被认为是先前轻度初始疾病的个体中严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染的晚期并发症,但导致长期心脏症状的潜在病理生理学仍不清楚。在这项研究中,我们通过测量心脏损伤或功能的血液生物标志物并进行磁共振成像,对患有 2019 年冠状病毒病(COVID-19)且无先前心脏疾病或明显合并症的选定人群进行了连续的心脏评估。从 346 名 COVID-19 患者(52%为女性)中获得的基线测量值中位数为感染后 109 天(四分位距(IQR),77-177 天),此时 73%的患者报告了心脏症状,如运动性呼吸困难(62%)、心悸(28%)、非典型胸痛(27%)和晕厥(3%)。与无症状个体相比,有症状个体的心率更高,影像学值或造影剂积聚更高,提示存在炎症性心脏受累。结构性心脏病或心脏损伤或功能的生物标志物水平较高在有症状个体中很少见。在随访时(感染后 329 天(IQR,274-383 天)),57%的参与者仍有持续性心脏症状。与症状改善的患者相比,在随访时仍有症状的患者弥漫性心肌水肿更为明显。女性性别和基线影像学上弥漫性心肌受累独立预测随访时存在心脏症状。持续性炎症性心脏受累可能至少部分解释了先前轻度 COVID-19 疾病个体中挥之不去的心脏症状。